Trailing twelve months where a flow is involved, latest reported balance where it is not.
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each quarter on its own, so seasonal highs and lows are visible.
-$24.01MQ3 2026-1.1%
What was left after every cost, including tax. Each quarter on its own, so seasonal highs and lows are visible.
-$8.75Q2 2026-58.8%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each quarter on its own, so seasonal highs and lows are visible.
2.71MQ2 2026+12.8%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each quarter on its own, so seasonal highs and lows are visible.
Everything above comes from BlossomHill Therapeutics, Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Not reported by this filer: Total Revenue, Cost of Revenue, Gross Profit, Profit Before Tax, Interest Expense, Income Tax Expense, Interest Income, Net Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Investments, Inventory, Receivables, Long-term Debt (noncurrent), Long-term Debt (current), Short-term Borrowings, Borrowings (total), Operating Lease (current), Finance Lease (current), Finance Lease Liabilities (total), Finance Lease (noncurrent), Dividends paid, Impairments, Depreciation & Amortization, Amortization of Intangibles, Share Repurchases, Change in Inventories, Change in Receivables, Change in Payables and Accruals, Change in Customer Advances, Change in Other Operating Capital, Change in Working Capital, Acquisitions, and Shares Issued for Cash. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
$14.07-6.1%Nov 13 close
The latest quarter (ended September 30, 2026) is from BlossomHill Therapeutics’s earnings press release of November 12, 2026. It will be replaced by the official quarterly report (10-Q) once BlossomHill Therapeutics files it.